Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Novartis”

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.Active Not Recruiting
NCT06379217Phase 1Updated Jul 24, 2026
Sponsor: Novartis Pharmaceuticals
Metastatic Neuroendocrine Prostate Cancer
United States, France, Germany, Spain, United Kingdom
HJB647 Phase 1b Study in Japanese Healthy Participants With Elevated Blood Pressure and Patients With HypertensionRecruiting
NCT07644364Phase 1Updated Jul 22, 2026
Sponsor: Novartis Pharmaceuticals
Elevated Blood Pressure · Hypertension
Japan
Pluvicto Real-world Investigation in Survival in Metastatic CRPCNot Yet Recruiting
NCT07697989N/AUpdated Jul 22, 2026
Sponsor: Novartis Pharmaceuticals
Prostatic Neoplasms, Castration-Resistant · Neoplasm Metastasis
A Real-world Study of Patients With Hidradenitis Suppurativa and High Cardiovascular Risk or Established Coronary Plaque Treated With SecukinumabNot Yet Recruiting
NCT07454889N/AUpdated Jul 22, 2026
Sponsor: Novartis Pharmaceuticals
Hidradenitis Suppurativa
Asciminib in HER2+ Breast Cancer Brain MetastasesRecruiting
NCT07136428Phase 1, Phase 2Updated Jul 22, 2026
Sponsor: Duke University
HER2+ Metastatic Breast Cancer
United States
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)Recruiting
NCT06649110Phase 1, Phase 2Updated Jul 21, 2026
Sponsor: Novartis Pharmaceuticals
Healthy Volunteers, Pulmonary Arterial Hypertension
United States, Argentina, Australia, Belgium, Brazil +13 more
A Study to Characterize the Clinical Presentation and Course of Cryptosporidium in Pediatric ParticipantsRecruiting
NCT07716410N/AUpdated Jul 21, 2026
Sponsor: Novartis Pharmaceuticals
Cryptosporidiosis
Kenya, Malaysia, Zambia
Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA NephropathyCompleted
NCT05834738Phase 2Updated Jul 20, 2026
Sponsor: Novartis Pharmaceuticals
IgA Nephropathy · Immunoglobulin A Nephropathy
United States, Australia, Brazil, Malaysia, South Korea +1 more
Study to Assess Safety and Clinical Responses With Coartem® Baby Dispersible Tablets in Paediatric Patients Weighing 2 to <5 kg With Uncomplicated MalariaNot Yet Recruiting
NCT07713602Phase 4Updated Jul 20, 2026
Sponsor: Novartis Pharmaceuticals
Malaria
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)Recruiting
NCT07387926Phase 1, Phase 2Updated Jul 20, 2026
Sponsor: Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia · Leukemia, Lymphoblastic, Acute, Philadelphia-Positive · Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Israel
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular DiseaseActive Not Recruiting
NCT05030428Phase 3Updated Jul 20, 2026
Sponsor: Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
United States, Argentina, Australia, Austria, Belgium +45 more
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell DiseaseRecruiting
NCT06546670Phase 1, Phase 2Updated Jul 20, 2026
Sponsor: Novartis Pharmaceuticals
Sickle Cell Disease
United States, Turkey (Türkiye)
Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa.Active Not Recruiting
NCT05921994N/AUpdated Jul 20, 2026
Sponsor: Novartis Pharmaceuticals
Hidradenitis Suppurativa
Germany
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-upActive Not Recruiting
NCT05677451Phase 3Updated Jul 20, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
United States, Argentina, Canada, Chile, China +12 more
Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian PopulationRecruiting
NCT07543419N/AUpdated Jul 20, 2026
Sponsor: Novartis Pharmaceuticals
Hidradenitis Suppurativa
Italy
A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) TherapyRecruiting
NCT07091019N/AUpdated Jul 20, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Myelogenous Leukemia - Chronic Phase
United States
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.Active Not Recruiting
NCT05109728Phase 1Updated Jul 17, 2026
Sponsor: Novartis Pharmaceuticals
Glioblastoma
United States, France, Portugal, Spain, Switzerland
A Real-World Study of Clinical Adoption, Treatment Patterns and Tolerability of Adjuvant Ribociclib in HR+/HER2- Early Breast Cancer PatientsActive Not Recruiting
NCT07710716N/AUpdated Jul 17, 2026
Sponsor: Novartis Pharmaceuticals
Breast Cancer
Switzerland
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in GermanyCompleted
NCT05305664Phase 3Updated Jul 17, 2026
Sponsor: Novartis Pharmaceuticals
Hyperlipoproteinemia(a)
Germany
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)Active Not Recruiting
NCT04603495Phase 3Updated Jul 17, 2026
Sponsor: Novartis Pharmaceuticals
Myelofibrosis · Primary Myelofibrosis · Post-polycythemia Vera Myelofibrosis · Post-essential Thrombocythemia Myelofibrosis
United States, Australia, Austria, Belgium, Canada +17 more
Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From IanalumabRecruiting
NCT07039422Phase 2Updated Jul 17, 2026
Sponsor: Novartis Pharmaceuticals
Primary Immune Thrombocytopenia · Warm Autoimmune Hemolytic Anemia
Argentina, Belgium, China, Czechia, France +9 more
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPCActive Not Recruiting
NCT05849298Phase 2Updated Jul 17, 2026
Sponsor: Novartis Pharmaceuticals
Prostatic Neoplasm
United States, Brazil, Canada, Czechia, France +6 more
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START TrialActive Not Recruiting
NCT01217931Phase 2Updated Jul 16, 2026
Sponsor: M.D. Anderson Cancer Center
Kidney Cancer
United States
Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With NilotinibCompleted
NCT00756509Phase 4Updated Jul 16, 2026
Sponsor: Novartis Pharmaceuticals
Gastrointestinal Stromal Tumors
Finland, France, Germany, Italy, Spain
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic MigraineActive Not Recruiting
NCT03836040Phase 3Updated Jul 16, 2026
Sponsor: Amgen
Migraine
United States, Belgium, Canada, Colombia, Finland +11 more

Previous page Next page